Primary spinal glioma in children: Results from a referral pediatric institution in Shanghai
| Autor: | J. Khalil, Y. Belkacémi, J. Mawei, Z. Qing, Z. Chuanying |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
China medicine.medical_specialty Pediatrics Adolescent medicine.medical_treatment Spinal Cord Glioma 03 medical and health sciences 0302 clinical medicine Glioma medicine Humans Radiology Nuclear Medicine and imaging Spinal Cord Neoplasms Progression-free survival Child Referral and Consultation Retrospective Studies Chemotherapy Temozolomide business.industry Infant Astrocytoma Hospitals Pediatric medicine.disease Surgery Radiation therapy Regimen Oncology Child Preschool 030220 oncology & carcinogenesis Female business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cancer/Radiothérapie. 21:261-266 |
| ISSN: | 1278-3218 |
| Popis: | Purpose Primary spinal cord glioma is a rare entity especially in children; accounting for less than 10% of all central nervous system tumors. Low grade is the most reported subtype. Treatment modalities have largely evolved; large improvements have been made in the surgical field but also in both of radiotherapy and chemotherapy. Nevertheless, the optimal treatment is yet to be defined. Material and methods A chart review of 11 pediatric patients with a diagnosis of low grade spinal cord glioma at Xhinhua hospital in Shanghai was conducted. A statistical package for Social Sciences Package (SPSS) was used for analysis. Means and standard deviations were calculated. The Kaplan-Meier method was used to analyze overall survival and progression-free survival. Results The mean age was 6.7 years (range: 6 months–14.3 years). Revealing symptoms were variable and slowly progressive. The mean duration of symptoms prior to diagnosis was of 7 ± 3.2 months. Astrocytoma was the most commonly reported histological type (seven cases, 63.6%), ependymomas were reported in three cases (27.3%). Surgery was performed in all patients. Subtotal resection concerned the majority of patients (nine patients, 81.8%). Adjuvant radiotherapy was indicated in all cases. A total dose of 39.6 Gy was delivered to the whole group. Three patients received adjuvant chemotherapy, of whom two patients had grade III glioma and one patient had a tumor recurrence. Temozolomide-based regimen was the main protocol used for all our patients. The 3 years overall survival rate was 100%, whereas the progression free survival rate was 87.5%. One case relapsed during the next year following completion of treatment. Conclusion Our preliminary results are consistent with that of other similar published reports, however longer follow up is needed. So are specific recommendations that are still lacking in this setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect